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Background: Routine prescription of proton-pump-inhibitors (PPI) in addition to clopidogrel and aspirin might be essential for prevention of 
gastrointestinal complications. However, it has been suggested that PPI might reduce the effect of clopidogrel and increase the risk of adverse 
thrombembolic events.
Methods: One thousand two hundred ten patients under dual antipaletet therapy, who underwent percoutaneous coronary intervention (PCI) and 
stent implantation, were included in a prospective registry from January 2003 until December 2006. The patients were divided retrospectively into 
those under PPI therapy and those without PPI. All-cause mortality and the combined endpoint all-cause death or stent thrombosis were evaluated 
over a follow-up period of 7,77 (± 3,63) months (range 1-12 months),
Results: Six hundred ninety one patients (56,8%) received PPIs at discharge while 519 patients (42,7%) were discharged without PPIs. Significant 
differences between the two groups existed for gender (male sex with PPI: 65,4% vs. without PPI: 72,6%, p=0,007), diabetes mellitus (with PPI: 
18,7% vs. without PPI: 26%, p=0,002), acute coronary syndrome at presentation (with PPI: 52,2% vs. without PPI 34,3%, p<0,001) and use of drug-
eluting stent (DES) (with PPI: 36,5% vs. without PPI: 29,5%, p=0,011).
All-cause mortality and the combined endpoint all-cause death or stent thrombosis did not differ significantly with respect to use or non-use of PPI 
therapy (2,2% vs. 2,1%, p=0,76 and 2,9% vs. 2,5%, p=0,69, respectively). After using the propensity score analysis to reduce the selection bias, there 
was no significant difference between the two groups with respect to all-cause mortality and the combined endpoint (2% vs. 2,2%, p=0,88, 2,7% vs. 
2,5%, p=0,69 respectively). Even in different subgroups of patients e.g. acute vs. elective, bare metal stent vs. DES, had concomitant PPI-therapy no 
significant influence on outcome.
Conclusions: Our data suggest that the combination of dual antiplatelet therapy with proton-pump inhibitors obviously does not significantly 
influence thrombembolic events.
